NIAID statement on AstraZeneca vaccine and AstraZeneca update

Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data. We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.

Authorization and guidelines for use of the vaccine in the United States will be determined by the Food and Drug Administration and Centers for Disease Control and Prevention after thorough review of the data by independent advisory committees.

Most Popular Now

Johnson & Johnson Announces Submission to Worl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization...

Sanofi to provide manufacturing support to Johnson…

Sanofi has entered into an agreement with Janssen Pharmaceutical NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, u...

Pfizer and BioNTech initiate a study as part of br…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTe...

Sanofi and GSK initiate new Phase 2 study of their…

Sanofi and GlaxoSmithKline (GSK) announced the initiation of a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Ph...

First COVID-19 COVAX vaccine doses administered in…

As the global rollout of COVAX vaccines accelerates, the first COVID-19 vaccination campaigns in Africa using COVAX doses began today in Ghana and Côte d'Ivoire. These ca...

Arthritis drugs may reduce mortality and time in I…

Treating critically ill COVID-19 patients with drugs typically used for rheumatoid arthritis may significantly improve survival, a landmark study has found. The findin...

Nanoparticle-delivered COVID-19 vaccine candidate …

Researchers from Cleveland Clinic's Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnol...

Researchers discover SARS-CoV-2 inhibitors

A research team of pharmacists at the University of Bonn has discovered two families of active substances that can block the replication of the SARS-CoV-2 coronavirus. Th...

Vaccine development software shows promise in infl…

A novel computer algorithm that could create a broadly reactive influenza vaccine for swine flu also offers a path toward a pan-influenza vaccine and possibly a pan-coron...

Assessing a compound's activity, not just its stru…

Assessing a drug compound by its activity, not simply its structure, is a new approach that could speed the search for COVID-19 therapies and reveal more potential therap...

Abbott researchers find rare group of people with …

Abbott (NYSE: ABT) announced today that a team of scientists has found an unusually high number of people in the Democratic Republic of Congo (DRC) who test positive for ...

AstraZeneca advances mass global rollout of COVID-…

The first of many millions of doses of AstraZeneca's COVID-19 vaccine have begun arriving in low and middle-income countries across the world through the multilateral COV...